List of Aliqopa drug patents
Aliqopa is owned by Bayer Healthcare.
Aliqopa contains Copanlisib Dihydrochloride.
Aliqopa has a total of 4 drug patents out of which 0 drug patents have expired.
Aliqopa was authorised for market use on 14 September, 2017.
Aliqopa is available in powder;intravenous dosage forms.
Aliqopa can be used as treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.
The generics of Aliqopa are possible to be released after 29 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(1 year, 1 month from now) | |
| USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(6 years from now) | |
| US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
ALIQOPA family patents
7
European Union
5
United States
3
Denmark
3
Slovenia
3
Argentina
3
Croatia
3
Portugal
3
Cyprus
3
Spain
3
Taiwan, Province of China
3
Ecuador
3
Japan
2
Israel
2
South Africa
2
Austria
2
Mexico
2
Australia
2
Hong Kong
2
Morocco
2
Uruguay
2
Brazil
2
Malaysia
2
Korea, Republic of
2
Poland
2
Peru
2
China
2
Ukraine
2
Canada
2
New Zealand
1
Russia
1
Jordan
1
Norway
1
Cuba
1
Costa Rica
1
AP
1
Germany
1
Singapore
1
Colombia
1
Guatemala
1
Dominican Republic
1
San Marino
1
Chile
1
RS
1
EA
1
Tunisia
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic